FLT3 inhibitors in AML: Current clinical landscape and key insights from trials
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
FLT3 inhibitors in AML: Current clinical landscape and key insights from trials
-
ナレーター：
-
著者：
The AML Hub was pleased to speak with Mark J. Levis, Johns Hopkins University, Baltimore, US. We asked, What is the current clinical landscape of FLT3 inhibitors in the treatment of AML, and what insights have been gained from trials so far?
Levis provides an overview of the key FLT3 inhibitors in clinical development for the treatment of FLT3-mutated (FLT3m) AML and discusses ongoing questions, including how to select the most appropriate FLT3 inhibitor for different patient populations and how best to incorporate them into standard treatment regimens. He highlights the value of measurable residual disease (MRD) in monitoring disease status as an important insight from clinical trials.
This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.
Hosted on Acast. See acast.com/privacy for more information.